Primary completion· ClinicalTrials.gov
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
BI 3000202 History and Updates
22 events · 2023 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
0
FDA Approvals
0
Label Revisions
22
Trial Milestones
0
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-07-08Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for BI 3000202 since 2023, drawn from openFDA, ClinicalTrials.gov, and PubMed.
All published updates (1)
2026
- Results postedBI 3000202 Phase 1 Study in Healthy Men Reports Safety and PK Food Effect· Jun 8, 2026
Upcoming & expected milestones
Primary completion· ClinicalTrials.gov
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
Primary completion· ClinicalTrials.gov
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Past events
2026
Results posted· ClinicalTrials.gov
A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood
Trial started· ClinicalTrials.gov
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
Trial started· ClinicalTrials.gov
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Trial registered· ClinicalTrials.gov
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
Primary completion· ClinicalTrials.gov
A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body
Trial registered· ClinicalTrials.gov
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
2025
Trial started· ClinicalTrials.gov
A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body
Trial registered· ClinicalTrials.gov
A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body
Primary completion· ClinicalTrials.gov
A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body
Trial started· ClinicalTrials.gov
A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body
Trial registered· ClinicalTrials.gov
A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body
Trial started· ClinicalTrials.gov
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
Trial registered· ClinicalTrials.gov
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
2024
Primary completion· ClinicalTrials.gov
A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazola
Trial started· ClinicalTrials.gov
A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazola
Trial registered· ClinicalTrials.gov
A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazola
2023
Primary completion· ClinicalTrials.gov
A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood
Trial started· ClinicalTrials.gov
A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood
Trial registered· ClinicalTrials.gov
A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.